A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This 4 arm study assessed the efficacy and safety of oral capecitabine (Xeloda) or
intravenous (iv) fluorouracil/leucovorin, in combination with iv oxaliplatin (Eloxatin) with
or without iv bevacizumab (Avastin), as a first-line treatment in patients with metastatic
colorectal cancer. Patients were randomized to receive 1) XELOX (Xeloda 1000 mg/m^2 orally
[po] twice a day [bid] on Days 1-15 + oxaliplatin in 3 week cycles), 2) FOLFOX-4 (oxaliplatin
+ leucovorin + fluorouracil [5-FU] in 2 week cycles), 3) XELOX + bevacizumab (7.5 mg iv on
Day 1 in 3 week cycles), or 4) FOLFOX-4 + bevacizumab (5 mg iv on Day 1 in 2 week cycles).